Indalpine

Indalpine
Clinical data
Trade names	Upstène
Other names	LM-5008
Identifiers
	IUPAC name 3-(2-piperidin-4-ylethyl)-1H-indole;
CAS Number	63758-79-2 ;
PubChem CID	44668;
DrugBank	DB08953 ;
ChemSpider	40643 ;
UNII	V35562QSVT;
ChEMBL	ChEMBL276520 ;
CompTox Dashboard (EPA)	DTXSID80213196 ;
ECHA InfoCard	100.058.569
Chemical and physical data
Formula	C15H20N2
Molar mass	228.339 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c2(c1ccccc1[nH]c2)CCC3CCNCC3;
	InChI InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2 ; Key:SADQVAVFGNTEOD-UHFFFAOYSA-N ;

Indalpine, sold under the brand name Upstène, is a selective serotonin reuptake inhibitor (SSRI) that was briefly marketed as an antidepressant for treatment of depression. It was marketed in France and a few other European countries.

Indalpine is a selective serotonin reuptake inhibitor (SSRI) and antihistamine.

Indalpine was invented by 1977 and was introduced for medical use in France in 1983. Two years later, in 1985, it was withdrawn from the market due to toxicity. Indalpine has sometimes been said to be the first SSRI. However, it was preceded by the SSRI zimelidine (Zelmid), which was invented in 1969 and was introduced to the market in 1981 (then similarly withdrawn due to toxicity in 1983).